Therapure Biopharma Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Therapure Biopharma Inc. - overview
Established
2008
Location
Mississauga, ON, Canada
Primary Industry
Pharmaceuticals
About
Founded in 2008 and based in Ontario, Canada, Therapure Biopharma Inc. operates as a contract development and manufacturing organization. In 2005, The Catalyst Capital Group acquired Hemosol Biopharma Inc. in a restructuring deal and later, rebranded the company as Therapure Biopharma Inc.
In 2017, 3SBio Inc. , Thunderpure International Limited, and a collection of funds from CITIC Private Equity Funds Management Co. , Ltd. acquired the contract development and manufacturing business of Therapure Biopharma Inc.
for USD 290 million and in October 2020, National Resilience, Inc. acquired the contract manufacturing organization assets of Therapure Biopharma Inc. As of 2010, the company has over 90 employees. Therapure Biopharma designs, manufactures, optimal biomanufacturing solutions.
The company provides a range of therapeutic protein development and manufacturing services including technology transfer & process development, analytical development and testing, scale-up and cGMP manufacturing, and aseptic fill/finish and lyophilization through its three divisions: therapure biomanufacturing, therapure innovations and evolve biologics. Therapure biomanufacturing deals with contract development and manufacturing of complex biologics. Therapure innovations is the company’s proprietary drug development division and evolve biologics uses Therapure Biopharma’s proprietary PlasmaCap EBA™ technology to develop a portfolio of plasma-derived pharmaceutical products. In 2017, Therapure Biopharma generated a revenue of USD 68.
8 million and an EBITDA of USD 18. 8 million.
Current Investors
The Catalyst Capital Group
Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.therapurebio.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Therapure Biopharma Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Therapure Biopharma Inc. | - | ||||||||
| Restructuring | Completed | Therapure Biopharma Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.